Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines

Journal of Controlled Release

Volumn 160, Issue 2, 2012, Pages 232-238

  Coimbra, Maria ^a   Crielaard, Bart J ^a   Storm, Gert ^a   Schiffelers, Raymond M ^a,b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NONE   (Netherlands)

Author keywords

Cancer; Drug delivery; Inflammation; Liposome; Natural compound

Indexed keywords

ARSENIC COMPOUNDS; BIOCHEMISTRY; CELL CULTURE; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; ESTERS; LIPOSOMES; MAMMALS; PATHOLOGY; TUMORS;

ANTI-INFLAMMATORY DRUGS; CAFFEIC ACID PHENETHYL ESTER; CANCER; INFLAMMATION; LIPOSOMAL FORMULATION; MEDICINAL APPLICATIONS; NATURAL COMPOUNDS; TUMOR ASSOCIATED MACROPHAGES;

TARGETED DRUG DELIVERY;

ANTIINFLAMMATORY AGENT; CAFFEIC ACID; CAFFEIC ACID PHENETHYL ESTER; CARVACROL; CARVACROL PHOSPHATE; LIPOSOME; N (3 OXODODECANOYL)HOMOSERINE LACTONE; PHENOL DERIVATIVE; PHOSPHATE BUFFERED SALINE; PREDNISOLONE SODIUM PHOSPHATE; PTEROSTILBENE PHOSPHATE; RESVERATROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTI INFLAMMATORY NANOMEDICINE; ARTICLE; CANCER THERAPY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MELANOMA; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL;

EID: 84861659639     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.10.019     Document Type: Article

References (61)

1. M. Khatami Unresolved inflammation: 'immune tsunami' or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer Expert Opin. Biol. Ther. 11 2011 1419 1432
2. A. Shanker, and F.M. Marincola Cooperativity of adaptive and innate immunity: implications for cancer therapy Cancer Immunol. Immunother. 8 2011 1061 1074
3. C.N. Serhan The resolution of inflammation: the devil in the flask and in the details FASEB J. 25 5 2011 1441 1448
4. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 6917 2002 860 867
5. S.C. Gupta, J.H. Kim, R. Kannappan, S. Reuter, P.M. Dougherty, and B.B. Aggarwal Role of nuclear factor-{kappa}B-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents Exp. Biol. Med. 236 6 2011 658 671
6. S.M. Soudja, M. Wehbe, A. Mas, L. Chasson, C.P. de Tenbossche, I. Huijbers, B. Van den Eynde, and A.M. Schmitt-Verhulst Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice Cancer Res. 70 9 2010 3515 3525
7. S. Demaria, E. Pikarsky, M. Karin, L.M. Coussens, Y.C. Chen, E.M. El-Omar, G. Trinchieri, S.M. Dubinett, J.T. Mao, E. Szabo, A. Krieg, G.J. Weiner, B.A. Fox, G. Coukos, E. Wang, R.T. Abraham, M. Carbone, and M.T. Lotze Cancer and inflammation: promise for biologic therapy J. Immunother. 33 4 2010 335 351
8. M.N.A. Khan, and Y.S. Lee Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy Med. Res. Rev. 31 2 2011 161 201
9. M. Coimbra, S.A. Kuijpers, S.P. van Seters, G. Storm, and R.M. Schiffelers Targeted delivery of anti-inflammatory agents to tumors Curr. Pharm. Des. 15 16 2009 1825 1843
10. M.K. Kim, K. Kim, J.Y. Han, J.M. Lim, and Y.S. Song Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer Genes Nutr. 6 2 2011 109 115
11. J. Mann Natural products in cancer chemotherapy: past, present and future Nat. Rev. Cancer 2 2 2002 143 148
12. R.G. Mehta, G. Murillo, R. Naithani, and X. Peng Cancer chemoprevention by natural products: how far have we come? Pharm. Res. 27 6 2010 950 961
13. R. Naithani, L.C. Huma, R.M. Moriarty, D.L. McCormick, and R.G. Mehta Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials Curr. Med. Chem. 15 11 2008 1044 1071
14. S. Nobili, D. Lippi, E. Witort, M. Donnini, L. Bausi, E. Mini, and S. Capaccioli Natural compounds for cancer treatment and prevention Pharmacol. Res. 59 6 2009 365 378
15. M.H. Pan, C.S. Lai, S. Dushenkov, and C.T. Ho Modulation of inflammatory genes by natural dietary bioactive compounds J. Agric. Food Chem. 57 11 2009 4467 4477
16. M. Schumacher, T. Juncker, M. Schnekenburger, F. Gaascht, and M. Diederich Natural compounds as inflammation inhibitors Genes Nutr. 6 2 2011 89 92
17. A.L. Harvey, R.L. Clark, S.P. Mackay, and B.F. Johnston Current strategies for drug discovery through natural products Expert Opin. Drug Discov. 5 6 2010 559 568
18. S.C. Gupta, J.H. Kim, S. Prasad, and B.B. Aggarwal Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals Cancer Metastasis Rev. 29 3 2010 405 434
19. Y. Shoji, and H. Nakashima Nutraceutics and delivery systems J. Drug Target. 12 6 2004 385 391
20. H.B. Nair, B. Sung, V.R. Yadav, R. Kannappan, M.M. Chaturvedi, and B.B. Aggarwal Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer Biochem. Pharmacol. 80 12 2010 1833 1843
21. M. Coimbra, B. Isacchi, L. van Bloois, J.S. Torano, A. Ket, X. Wu, F. Broere, J.M. Metselaar, C.J. Rijcken, G. Storm, R. Bilia, and R.M. Schiffelers Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes Int. J. Pharm. 416 2 2011 433 442
22. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 12 Pt 1 1986 6387 6392
23. Y.H. Bae, and K. Park Targeted drug delivery to tumors: Myths, reality and possibility J. Control. Release 153 3 2011 198 205
24. B.S. Sandanaraj, H.U. Gremlich, R. Kneuer, J. Dawson, and S. Wacha Fluorescent nanoprobes as a biomarker for increased vascular permeability: implications in diagnosis and treatment of cancer and inflammation Bioconjug. Chem. 21 1 2010 93 101
25. D.B. Fenske, and P.R. Cullis Liposomal nanomedicines Expert Opin. Drug Deliv. 5 1 2008 25 44
26. S. Fulda Resveratrol and derivatives for the prevention and treatment of cancer Drug Discov. Today 15 17-18 2010 757 765
27. R. Gonzalez, I. Ballester, R. Lopez-Posadas, M.D. Suarez, A. Zarzuelo, O. Martinez-Augustin, and F. Sanchez de Medina Effects of flavonoids and other polyphenols on inflammation Crit. Rev. Food Sci. Nutr. 51 4 2011 331 362
28. J. Ha, H.S. Choi, Y. Lee, Z.H. Lee, and H.H. Kim Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos Int. Immunopharmacol. 9 6 2009 774 780
29. M. Hotta, R. Nakata, M. Katsukawa, K. Hori, S. Takahashi, and H. Inoue Carvacrol, a component of thyme oil, activates PPARalpha and gamma and suppresses COX-2 expression J. Lipid Res. 51 1 2010 132 139
30. V.V. Kravchenko, G.F. Kaufmann, J.C. Mathison, D.A. Scott, A.Z. Katz, D.C. Grauer, M. Lehmann, M.M. Meijler, K.D. Janda, and R.J. Ulevitch Modulation of gene expression via disruption of NF-kappaB signaling by a bacterial small molecule Science 321 5886 2008 259 263
31. M.K. Moon, Y.J. Lee, J.S. Kim, D.G. Kang, and H.S. Lee Effect of caffeic acid on tumor necrosis factor-alpha-induced vascular inflammation in human umbilical vein endothelial cells Biol. Pharm. Bull. 32 8 2009 1371 1377
32. S. Paul, A.M. Rimando, H.J. Lee, Y. Ji, B.S. Reddy, and N. Suh Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells Cancer Prev. Res. (Phila) 2 7 2009 650 657
33. K.M. Arunasree Anti-proliferative effects of carvacrol on a human metastatic breast cancer cell line, MDA-MB 231 Phytomedicine 17 8-9 2010 581 588
34. S. Bhattacharya, S.R. Darjatmoko, and A.S. Polans Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB Melanoma Res. 21 3 2011 180 187
35. W.C. Chang, C.H. Hsieh, M.W. Hsiao, W.C. Lin, Y.C. Hung, and J.C. Ye Caffeic acid induces apoptosis in human cervical cancer cells through the mitochondrial pathway Taiwan J. Obstet. Gynecol. 49 4 2011 419 424
36. P. Ferrer, M. Asensi, R. Segarra, A. Ortega, M. Benlloch, E. Obrador, M.T. Varea, G. Asensio, L. Jorda, and J.M. Estrela Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma Neoplasia 7 1 2005 37 47
37. J.E. Jung, H.S. Kim, C.S. Lee, D.H. Park, Y.N. Kim, M.J. Lee, J.W. Lee, J.W. Park, M.S. Kim, S.K. Ye, and M.H. Chung Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells Carcinogenesis 28 8 2007 1780 1787
38. S.K. Kudugunti, N.M. Vad, E. Ekogbo, and M.Y. Moridani Efficacy of caffeic acid phenethyl ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice Invest. New Drugs 29 1 2009 52 62
39. S.K. Kudugunti, N.M. Vad, A.J. Whiteside, B.U. Naik, M.A. Yusuf, K.S. Srivenugopal, and M.Y. Moridani Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines Chem. Biol. Interact. 188 1 2010 1 14
40. L. Li, D. Hooi, S.R. Chhabra, D. Pritchard, and P.E. Shaw Bacterial N-acylhomoserine lactone-induced apoptosis in breast carcinoma cells correlated with down-modulation of STAT3 Oncogene 23 28 2004 4894 4902
41. P.W. Mannal, J.A. Alosi, J.G. Schneider, D.E. McDonald, and D.W. McFadden Pterostilbene inhibits pancreatic cancer in vitro J. Gastrointest. Surg. 14 5 2010 873 879
42. M.H. Pan, Y.S. Chiou, W.J. Chen, J.M. Wang, V. Badmaev, and C.T. Ho Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells Carcinogenesis 30 7 2009 1234 1242
43. C. Salado, E. Olaso, N. Gallot, M. Valcarcel, E. Egilegor, L. Mendoza, and F. Vidal-Vanaclocha Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18 J. Transl. Med. 9 2011 59
44. Y.P. Yang, Y.L. Chang, P.I. Huang, G.Y. Chiou, L.M. Tseng, S.H. Chiou, M.H. Chen, M.T. Chen, Y.H. Shih, C.H. Chang, C.C. Hsu, H.I. Ma, C.T. Wang, L.L. Tsai, C.C. Yu, and C.J. Chang Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis J. Cell. Physiol. 2011 2011 Apr 18. doi: 10.1002/jcp.22806 [ahead of print]
45. G. Rouser, S. Fkeischer, and A. Yamamoto Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots Lipids 5 5 1970 494 496
46. M. Voinea, and M. Simionescu Designing of 'intelligent' liposomes for efficient delivery of drugs J. Cell. Mol. Med. 6 4 2002 465 474
47. M. Mutoh, M. Takahashi, K. Fukuda, Y. Matsushima-Hibiya, H. Mutoh, T. Sugimura, and K. Wakabayashi Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure Carcinogenesis 21 5 2000 959 963
48. S. Shah, A.A. Divekar, S.P. Hilchey, H.M. Cho, C.L. Newman, S.U. Shin, H. Nechustan, P.M. Challita-Eid, B.M. Segal, K.H. Yi, and J.D. Rosenblatt Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells Int. J. Cancer 117 4 2005 574 586
49. D.-J. Cheon, and S. Orsulic Mouse Models of Cancer Annu. Rev. Pathol. Mech. Dis. 6 1 2011 95 119
50. C. Abate-Shen, P.H. Brown, N.H. Colburn, E.W. Gerner, J.E. Green, M. Lipkin, W.G. Nelson, and D. Threadgill The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges Cancer Prev. Res. 1 3 2008 161 166
51. T. Van Dyke, and T. Jacks Cancer Modeling in the Modern Era: Progress and Challenges Cell 108 2 2002 135 144
52. R.M. Schiffelers, J.M. Metselaar, M.H. Fens, A.P. Janssen, G. Molema, and G. Storm Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice Neoplasia 7 2 2005 118 127
53. J. Ehrchen, L. Steinmuller, K. Barczyk, K. Tenbrock, W. Nacken, M. Eisenacher, U. Nordhues, C. Sorg, C. Sunderkotter, and J. Roth Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes Blood 109 3 2007 1265 1274
54. H.C. Kuo, W.H. Kuo, Y.J. Lee, W.L. Lin, F.P. Chou, and T.H. Tseng Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo Cancer Lett. 234 2 2006 199 208
55. J. Wu, C. Omene, J. Karkoszka, M. Bosland, J. Eckard, C.B. Klein, and K. Frenkel Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer Cancer Lett. 308 1 2011 43 53
56. G. Storm, P.A. Steerenberg, F. Emmen, M. van Borssum Waalkes, and D.J. Crommelin Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes Biochim. Biophys. Acta 965 2-3 1988 136 145
57. P.S. Steyger, D.F. Baban, M. Brereton, K. Ulbrich, and L.W. Seymour Intratumoural distribution as a determinant of tumour responsiveness to therapy using polymer-based macromolecular prodrugs J. Control. Release 39 1 1996 35 46
58. E. Kluza, S.Y. Yeo, S. Schmid, D.W. van der Schaft, R.W. Boekhoven, R.M. Schiffelers, G. Storm, G.J. Strijkers, and K. Nicolay Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity J. Control. Release 151 1 2011 10 17
59. S. Grosch, T.J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors J. Natl. Cancer Inst. 98 11 2006 736 747
60. L. Li, F.S. Braiteh, and R. Kurzrock Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis Cancer 104 6 2005 1322 1331
61. M. Coimbra, M. Banciu, M.H. Fens, L. de Smet, M. Cabaj, J.M. Metselaar, G. Storm, and R.M. Schiffelers Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation J. Control. Release 148 3 2011 303 310